Fuzionaire RI Technologies

Fuzionaire RI is a biotechnology company specializing in the development of next-generation radiopharmaceuticals using a proprietary alkali metal catalysis platform. The company's technology, originally developed at Caltech, enables the rapid and efficient incorporation of radioisotopes like Fluorine-18 into complex molecules for PET imaging and targeted radiotherapy. By providing a more versatile and site-specific labeling method, Fuzionaire RI aims to expand the library of available tracers and therapeutic agents for oncology and neurology. The platform is designed to overcome the chemical constraints of traditional radiolabeling, allowing for the creation of novel diagnostic and therapeutic candidates. Fuzionaire RI collaborates with pharmaceutical partners to radiolabel their proprietary assets, accelerating the development of precision medicines.